ExpreS2ion Biotech Holding AB: Listing process delayed

ExpreS2ion Biotech Holding AB herby announces that the listing process at Nasdaq Stockholm First North has been delayed. The company will return shortly with more information

Financial Advisors and Certified Advisor

Sedermera Fondkommission is appointed as Certified Adviser for the Company

For further information about ExpreS2ion, please contact:

Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CET, July the 27th 2016.

About ExpreS2ion

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.

Tags: